Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
Stopped On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.
Conditions
Interventions
- DRUG: Dapagliflozin
- DRUG: Placebo
Sponsor
Hellenic Society for Medical Education